{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:56:03Z","timestamp":1790697363684,"version":"4.1.0"},"reference-count":70,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical Science Research Project of Hebei","award":["20261147"],"award-info":[{"award-number":["20261147"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Cardiovasc. Med."],"abstract":"<jats:p>Inflammation plays a key role in the onset and progression of heart failure (HF) after myocardial infarction (MI), which represents one of the leading causes of mortality in patients with cardiovascular disease. This review summarizes the inflammatory mechanisms involved at different stages of HF after MI, including the infiltration and activation of inflammatory cells, the release of inflammatory mediators, and the effects of these mediators on cardiomyocytes, the extracellular matrix, and cardiac function. In addition, this review discusses therapeutic strategies that target inflammatory pathways, providing a theoretical basis for the prevention and treatment of HF after MI.<\/jats:p>","DOI":"10.31083\/rcm49888","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:57:11Z","timestamp":1790693831000},"source":"Crossref","is-referenced-by-count":0,"title":["Role of Inflammation in the Development of Heart Failure After Myocardial Infarction"],"prefix":"10.31083","volume":"27","author":[{"given":"Yachao","family":"Li","sequence":"first","affiliation":[{"name":"Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang People\u2019s Hospital, 065000 Langfang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9940-2488","authenticated-orcid":true,"given":"Mengjie","family":"Lei","sequence":"additional","affiliation":[{"name":"Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang People\u2019s Hospital, 065000 Langfang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9302-9547","authenticated-orcid":true,"given":"Zengming","family":"Xue","sequence":"additional","affiliation":[{"name":"Langfang Core Laboratory of Precision Treatment of Coronary Artery Disease, Langfang People\u2019s Hospital, 065000 Langfang, Hebei, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Stiermaier T, Eitel I, de Waha S, P\u00f6ss J, Fuernau G, Thiele H, et al. Myocardial salvage after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction presenting early versus late after symptom onset. The International Journal of Cardiovascular Imaging. 2017; 33: 1571\u20131579.","DOI":"10.1007\/s10554-017-1143-x"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Timmers L, Pasterkamp G, de Hoog VC, Arslan F, Appelman Y, de Kleijn DPV. The innate immune response in reperfused myocardium. Cardiovascular Research. 2012; 94: 276\u2013283.","DOI":"10.1093\/cvr\/cvs018"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Ghigo A, Franco I, Morello F, Hirsch E. Myocyte signalling in leucocyte recruitment to the heart. Cardiovascular Research. 2014; 102: 270\u2013280.","DOI":"10.1093\/cvr\/cvu030"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Zhang Q, Wang L, Wang S, Cheng H, Xu L, Pei G, et al. Signaling pathways and targeted therapy for myocardial infarction. Signal Transduction and Targeted Therapy. 2022; 7: 78.","DOI":"10.1038\/s41392-022-00925-z"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Frangogiannis NG. S100A8\/A9 as a therapeutic target in myocardial infarction: cellular mechanisms, molecular interactions, and translational challenges. European Heart Journal. 2019; 40: 2724\u20132726.","DOI":"10.1093\/eurheartj\/ehz524"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Ma J, Li Y, Li P, Yang X, Zhu S, Ma K, et al. S100A8\/A9 as a prognostic biomarker with causal effects for post-acute myocardial infarction heart failure. Nature Communications. 2024; 15: 2701.","DOI":"10.1038\/s41467-024-46973-7"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Vlad ML, Mares RG, Jakobsson G, Manea SA, Lazar AG, Preda MB, et al. Therapeutic S100A8\/A9 inhibition reduces NADPH oxidase expression, reactive oxygen species production and NLRP3 inflammasome priming in the ischemic myocardium. European Journal of Pharmacology. 2025; 996: 177575.","DOI":"10.1016\/j.ejphar.2025.177575"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. The New England Journal of Medicine. 2007; 357: 1121\u20131135.","DOI":"10.1056\/NEJMra071667"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Frangogiannis NG. Regulation of the inflammatory response in cardiac repair. Circulation Research. 2012; 110: 159\u2013173.","DOI":"10.1161\/CIRCRESAHA.111.243162"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Kain V, Prabhu SD, Halade GV. Inflammation revisited: inflammation versus resolution of inflammation following myocardial infarction. Basic Research in Cardiology. 2014; 109: 444.","DOI":"10.1007\/s00395-014-0444-7"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Eltzschig HK, Eckle T. Ischemia and reperfusion--from mechanism to translation. Nature Medicine. 2011; 17: 1391\u20131401.","DOI":"10.1038\/nm.2507"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Vandervelde S, van Amerongen MJ, Tio RA, Petersen AH, van Luyn MJA, Harmsen MC. Increased inflammatory response and neovascularization in reperfused vs. non-reperfused murine myocardial infarction. Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology. 2006; 15: 83\u201390.","DOI":"10.1016\/j.carpath.2005.10.006"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Prabhu SD, Frangogiannis NG. The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis. Circulation Research. 2016; 119: 91\u2013112.","DOI":"10.1161\/CIRCRESAHA.116.303577"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Jiao Y, Zhang T, Zhang C, Ji H, Tong X, Xia R, et al. Exosomal miR-30d-5p of neutrophils induces M1 macrophage polarization and primes macrophage pyroptosis in sepsis-related acute lung injury. Critical Care (London, England). 2021; 25: 356.","DOI":"10.1186\/s13054-021-03775-3"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Halade GV, Tourki B. Specialized Pro-resolving Mediators Directs Cardiac Healing and Repair with Activation of Inflammation and Resolution Program in Heart Failure. Advances in Experimental Medicine and Biology. 2019; 1161: 45\u201364.","DOI":"10.1007\/978-3-030-21735-8_6"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Serhan CN, Levy BD. Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. The Journal of Clinical Investigation. 2018; 128: 2657\u20132669.","DOI":"10.1172\/JCI97943"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Jaggi AS, Singh M, Sharma A, Singh D, Singh N. Cardioprotective effects of mast cell modulators in ischemia-reperfusion-induced injury in rats. Methods and Findings in Experimental and Clinical Pharmacology. 2007; 29: 593\u2013600.","DOI":"10.1358\/mf.2007.29.9.1161005"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Peet C, Ivetic A, Bromage DI, Shah AM. Cardiac monocytes and macrophages after myocardial infarction. Cardiovascular Research. 2020; 116: 1101\u20131112.","DOI":"10.1093\/cvr\/cvz336"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Tourki B, Halade G. Leukocyte diversity in resolving and nonresolving mechanisms of cardiac remodeling. FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology. 2017; 31: 4226\u20134239.","DOI":"10.1096\/fj.201700109R"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Ma Y, Yabluchanskiy A, Lindsey ML. Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogenesis & Tissue Repair. 2013; 6: 11.","DOI":"10.1186\/1755-1536-6-11"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Horckmans M, Ring L, Duchene J, Santovito D, Schloss MJ, Drechsler M, et al. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. European Heart Journal. 2017; 38: 187\u2013197.","DOI":"10.1093\/eurheartj\/ehw002"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Beyer M, Mallmann MR, Xue J, Staratschek-Jox A, Vorholt D, Krebs W, et al. High-resolution transcriptome of human macrophages. PloS One. 2012; 7: e45466.","DOI":"10.1371\/journal.pone.0045466"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Shinde AV, Frangogiannis NG. Fibroblasts in myocardial infarction: a role in inflammation and repair. Journal of Molecular and Cellular Cardiology. 2014; 70: 74\u201382.","DOI":"10.1016\/j.yjmcc.2013.11.015"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"Dobaczewski M, Xia Y, Bujak M, Gonzalez-Quesada C, Frangogiannis NG. CCR5 signaling suppresses inflammation and reduces adverse remodeling of the infarcted heart, mediating recruitment of regulatory T cells. The American Journal of Pathology. 2010; 176: 2177\u20132187.","DOI":"10.2353\/ajpath.2010.090759"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Bujak M, Dobaczewski M, Chatila K, Mendoza LH, Li N, Reddy A, et al. Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodeling. The American Journal of Pathology. 2008; 173: 57\u201367.","DOI":"10.2353\/ajpath.2008.070974"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Li M, Zhang Y, Hu Y, Qin Y, Zheng Y, Lv S, et al. Mitochondrial homeostasis meets novel programmed cell death: crosstalk mechanisms underlying cardiovascular diseases progression. Cell Communication and Signaling : CCS. 2026; 24: 100.","DOI":"10.1186\/s12964-026-02673-x"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Li T, Wang N, Yi D, Xiao Y, Li X, Shao B, et al. ROS-mediated ferroptosis and pyroptosis in cardiomyocytes: An update. Life Sciences. 2025; 370: 123565.","DOI":"10.1016\/j.lfs.2025.123565"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Larose E, Rod\u00e9s-Cabau J, Pibarot P, Rinfret S, Proulx G, Nguyen CM, et al. Predicting late myocardial recovery and outcomes in the early hours of ST-segment elevation myocardial infarction traditional measures compared with microvascular obstruction, salvaged myocardium, and necrosis characteristics by cardiovascular magnetic resonance. Journal of the American College of Cardiology. 2010; 55: 2459\u20132469.","DOI":"10.1016\/j.jacc.2010.02.033"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"van Diepen S, Newby LK, Lopes RD, Stebbins A, Hasselblad V, James S, et al. Prognostic relevance of baseline pro- and anti-inflammatory markers in STEMI: an APEX AMI substudy. International Journal of Cardiology. 2013; 168: 2127\u20132133.","DOI":"10.1016\/j.ijcard.2013.01.004"},{"key":"ref30","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA Guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2022; 79: e263\u2013e421."},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2023; 44: 3627\u20133639.","DOI":"10.1093\/eurheartj\/ehad195"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nature Reviews. Cardiology. 2021; 18: 400\u2013423.","DOI":"10.1038\/s41569-020-00480-6"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. Journal of the American College of Cardiology. 2013; 62: 263\u2013271.","DOI":"10.1016\/j.jacc.2013.02.092"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Fayyaz AU, Eltony M, Prokop LJ, Koepp KE, Borlaug BA, Dasari S, et al. Pathophysiological insights into HFpEF from studies of human cardiac tissue. Nature Reviews. Cardiology. 2025; 22: 90\u2013104.","DOI":"10.1038\/s41569-024-01067-1"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Hybiak J, Broniarek I, Kiryczy\u0144ski G, Los LD, Rosik J, Machaj F, et al. Aspirin and its pleiotropic application. European Journal of Pharmacology. 2020; 866: 172762.","DOI":"10.1016\/j.ejphar.2019.172762"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Antithrombotic Trialists' (ATT) Collaboration, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (London, England). 2009; 373: 1849\u20131860.","DOI":"10.1016\/S0140-6736(09)60503-1"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Santilli F, Rocca B, De Cristofaro R, Lattanzio S, Pietrangelo L, Habib A, et al. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin \"resistance\". Journal of the American College of Cardiology. 2009; 53: 667\u2013677.","DOI":"10.1016\/j.jacc.2008.10.047"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Connolly SJ, Eikelboom JW, Bosch J, Dagenais G, Dyal L, Lanas F, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. The Lancet. 2018; 391: 205\u2013218.","DOI":"10.1016\/S0140-6736(17)32458-3"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021; 42: 3599\u20133726.","DOI":"10.1093\/eurheartj\/ehab368"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Almeida SO, Budoff M. Effect of statins on atherosclerotic plaque. Trends in Cardiovascular Medicine. 2019; 29: 451\u2013455.","DOI":"10.1016\/j.tcm.2019.01.001"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Sakellarios AI, Fotiadis DI. Editorial commentary: The pleiotropic effect of statins on the atherosclerotic plaque and coronary heart disease. Trends in Cardiovascular Medicine. 2019; 29: 456\u2013457.","DOI":"10.1016\/j.tcm.2019.02.001"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Stumpf C, Petzi S, Seybold K, Wasmeier G, Arnold M, Raaz D, et al. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction. Clinical Science (London, England : 1979). 2009; 116: 45\u201352.","DOI":"10.1042\/CS20080042"},{"key":"ref43","doi-asserted-by":"publisher","unstructured":"Shen Y, Wu H, Wang C, Shao H, Huang H, Jing H, et al. Simvastatin attenuates cardiopulmonary bypass-induced myocardial inflammatory injury in rats by activating peroxisome proliferator-activated receptor \u03b3. European Journal of Pharmacology. 2010; 649: 255\u2013262.","DOI":"10.1016\/j.ejphar.2010.08.058"},{"key":"ref44","doi-asserted-by":"publisher","unstructured":"Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. The New England Journal of Medicine. 2008; 359: 2195\u20132207.","DOI":"10.1056\/NEJMoa0807646"},{"key":"ref45","doi-asserted-by":"publisher","unstructured":"Tardif JC, Kouz S, Waters DD, Bertrand OF, Diaz R, Maggioni AP, et al. Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. The New England Journal of Medicine. 2019; 381: 2497\u20132505.","DOI":"10.1056\/NEJMoa1912388"},{"key":"ref46","doi-asserted-by":"publisher","unstructured":"Nidorf M, Thompson PL. Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. The American Journal of Cardiology. 2007; 99: 805\u2013807.","DOI":"10.1016\/j.amjcard.2006.10.039"},{"key":"ref47","doi-asserted-by":"publisher","unstructured":"Bouabdallaoui N, Tardif JC, Waters DD, Pinto FJ, Maggioni AP, Diaz R, et al. Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT). European Heart Journal. 2020; 41: 4092\u20134099.","DOI":"10.1093\/eurheartj\/ehaa659"},{"key":"ref48","doi-asserted-by":"publisher","unstructured":"Nidorf SM, Thompson PL. Why Colchicine Should Be Considered for Secondary Prevention of Atherosclerosis: An Overview. Clinical Therapeutics. 2019; 41: 41\u201348.","DOI":"10.1016\/j.clinthera.2018.11.016"},{"key":"ref49","doi-asserted-by":"publisher","unstructured":"Kaplinsky E. DAPA-HF trial: dapagliflozin evolves from a glucose-lowering agent to a therapy for heart failure. Drugs in Context. 2020; 9: 2019\u201311\u20133.","DOI":"10.7573\/dic.2019-11-3"},{"key":"ref50","doi-asserted-by":"publisher","unstructured":"B\u00f6hm M, Butler J, Coats A, Lauder L, Mahfoud F, Filippatos G, et al. Empagliflozin in resistant hypertension and heart failure with preserved ejection fraction: the EMPEROR-Preserved trial. European Heart Journal. 2025; 46: 1304\u20131317.","DOI":"10.1093\/eurheartj\/ehae938"},{"key":"ref51","doi-asserted-by":"publisher","unstructured":"Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine. 2022; 387: 1089\u20131098.","DOI":"10.1056\/NEJMoa2206286"},{"key":"ref52","doi-asserted-by":"publisher","unstructured":"Robert A, Demetrio Sharp D, Jennifer L C, Mahyar P. SGLT-2 INHIBITORS ARE EFFICACIOUS IN HIGH-RISK SUBGROUPS OF PATIENTS WITH HEART FAILURE WITH MILDLY REDUCED OR PRESERVED EJECTION FRACTION. Journal of the American College of Cardiology. 2023; 81: (8_Supplement) 277. https:\/\/www.jacc.org\/doi\/","DOI":"10.1016\/S0735-1097(23)00721-0"},{"key":"ref53","doi-asserted-by":"publisher","unstructured":"Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. European Journal of Heart Failure. 2019; 21: 1279\u20131287.","DOI":"10.1002\/ejhf.1596"},{"key":"ref54","doi-asserted-by":"publisher","unstructured":"Yoo TT, Baek IH, Stoletniy L, Hilliard A, Sakr A, Doycheva D. Impact of sodium-glucose transport protein-2 (SGLT2) inhibitors on the inflammasome pathway in acute myocardial infarction in type 2 diabetes mellitus: a comprehensive review. Cardiovascular Diabetology. 2025; 24: 227.","DOI":"10.1186\/s12933-025-02777-7"},{"key":"ref55","doi-asserted-by":"publisher","unstructured":"Checa-Ros A, Okojie OJ, D'Marco L. SGLT2 Inhibitors: Multifaceted Therapeutic Agents in Cardiometabolic and Renal Diseases. Metabolites. 2025; 15: 536.","DOI":"10.3390\/metabo15080536"},{"key":"ref56","doi-asserted-by":"publisher","unstructured":"De Lorenzi AB, Kaplinsky E, Zambrano MR, Chaume LT, Rosas JM. Emerging concepts in heart failure management and treatment: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction. Drugs in Context. 2023; 12: 2022\u20137\u20131.","DOI":"10.7573\/dic.2022-7-1"},{"key":"ref57","doi-asserted-by":"publisher","unstructured":"Leite S, Moreira-Costa L, Cerqueira R, Sousa-Mendes C, Ang\u00e9lico-Gon\u00e7alves A, Fontoura D, et al. Chronic Sildenafil Therapy in the ZSF1 Obese Rat Model of Metabolic Syndrome and Heart Failure With Preserved Ejection Fraction. Journal of Cardiovascular Pharmacology and Therapeutics. 2021; 26: 690\u2013701.","DOI":"10.1177\/10742484211034253"},{"key":"ref58","doi-asserted-by":"publisher","unstructured":"Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, et al. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. The New England Journal of Medicine. 2017; 377: 1119\u20131131.","DOI":"10.1056\/NEJMoa1707914"},{"key":"ref59","doi-asserted-by":"publisher","unstructured":"Ikonomidis I, Pavlidis G, Katsimbri P, Andreadou I, Triantafyllidi H, Tsoumani M, et al. Differential effects of inhibition of interleukin 1 and 6 on myocardial, coronary and vascular function. Clinical Research in Cardiology : Official Journal of the German Cardiac Society. 2019; 108: 1093\u20131101.","DOI":"10.1007\/s00392-019-01443-9"},{"key":"ref60","doi-asserted-by":"publisher","unstructured":"Kleveland O, Kunszt G, Bratlie M, Ueland T, Broch K, Holte E, et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. European Heart Journal. 2016; 37: 2406\u20132413.","DOI":"10.1093\/eurheartj\/ehw171"},{"key":"ref61","doi-asserted-by":"publisher","unstructured":"Bergstr\u00f6m U, Jovinge S, Persson J, Jacobsson LTH, Turesson C. Effects of Treatment with Adalimumab on Blood Lipid Levels and Atherosclerosis in Patients with Rheumatoid Arthritis. Current Therapeutic Research, Clinical and Experimental. 2018; 89: 1\u20136.","DOI":"10.1016\/j.curtheres.2018.07.001"},{"key":"ref62","doi-asserted-by":"publisher","unstructured":"Chen XY, Yan BX, Man XY. TNF\u03b1 inhibitor may be effective for severe COVID-19: learning from toxic epidermal necrolysis. Therapeutic Advances in Respiratory Disease. 2020; 14: 1753466620926800.","DOI":"10.1177\/1753466620926800"},{"key":"ref63","doi-asserted-by":"publisher","unstructured":"Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT, Anti-TNF Therapy Against Congestive Heart Failure Investigators. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation. 2003; 107: 3133\u20133140.","DOI":"10.1161\/01.CIR.0000077913.60364.D2"},{"key":"ref64","doi-asserted-by":"publisher","unstructured":"Mann DL, McMurray JJV, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation. 2004; 109: 1594\u20131602.","DOI":"10.1161\/01.CIR.0000124490.27666.B2"},{"key":"ref65","doi-asserted-by":"publisher","unstructured":"Deshmukh T, Hume RD, Chen S, Igoor S, Foster SL, Barry T, et al. Platelet derived growth factor-AB modulates post-infarct myocardium leading to extended improvement in cardiac function. NPJ Regenerative Medicine. 2025; 10: 46.","DOI":"10.1038\/s41536-025-00433-y"},{"key":"ref66","unstructured":"ClinicalTrials.gov. Platelet Derived Growth Factor Receptor \u00df (PDGFR\u00df) Imaging in Cardiac Fibrosis (PARIS). 2025. Available at: https:\/\/clinicaltrials.gov\/study\/NCT06956560?cond=NCT06956560&viewType=Card&rank=1 (Accessed: 11 January 2026)."},{"key":"ref67","doi-asserted-by":"publisher","unstructured":"Marinkovi\u0107 G, Grauen Larsen H, Yndigegn T, Szabo IA, Mares RG, de Camp L, et al. Inhibition of pro-inflammatory myeloid cell responses by short-term S100A9 blockade improves cardiac function after myocardial infarction. European Heart Journal. 2019; 40: 2713\u20132723.","DOI":"10.1093\/eurheartj\/ehz461"},{"key":"ref68","doi-asserted-by":"publisher","unstructured":"Yu Y, Shi H, Wang Y, Yu Y, Chen R. A pilot study of S100A4, S100A8\/A9, and S100A12 in dilated cardiomyopathy: novel biomarkers for diagnosis or prognosis? ESC Heart Failure. 2024; 11: 503\u2013512.","DOI":"10.1002\/ehf2.14605"},{"key":"ref69","doi-asserted-by":"publisher","unstructured":"Volz HC, Laohachewin D, Seidel C, Lasitschka F, Keilbach K, Wienbrandt AR, et al. S100A8\/A9 aggravates post-ischemic heart failure through activation of RAGE-dependent NF-\u03baB signaling. Basic Research in Cardiology. 2012; 107: 250.","DOI":"10.1007\/s00395-012-0250-z"},{"key":"ref70","doi-asserted-by":"publisher","unstructured":"Imbesi A, Greco A, Spagnolo M, Laudani C, Raffo C, Finocchiaro S, et al. Targeting Inflammation After Acute Myocardial Infarction. Journal of the American College of Cardiology. 2025; 86: 1146\u20131169.","DOI":"10.1016\/j.jacc.2025.07.064"}],"container-title":["Reviews in Cardiovascular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/9\/10.31083\/RCM49888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:57:18Z","timestamp":1790693838000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/RCM\/27\/9\/10.31083\/RCM49888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":70,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2153-8174(26)04678-0"],"URL":"https:\/\/doi.org\/10.31083\/rcm49888","relation":{},"ISSN":["1530-6550","2153-8174"],"issn-type":[{"value":"1530-6550","type":"print"},{"value":"2153-8174","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"49888"}}